Full Product Name
JAK2 siRNA (Human)
Product Synonym Names
Tyrosine-protein kinase JAK2; Janus kinase 2; JAK-2
Product Gene Name
JAK2 sirna
[Similar Products]
Research Use Only
For Research Use Only. Not for use in diagnostic procedures.
3D Structure
ModBase 3D Structure for O60674
Specificity
JAK2 siRNA (Human) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
Purity/Purification
> 97%
Form/Format
Lyophilized powder
Quality Control
Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
Directions for Use
We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
Components
We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of human JAK2 gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
Preparation and Storage
Shipped at 4 degree C. Store at -20 degree C for one year.
Negative Control
siRNA Negative Control (Catalog# MBS8241404) is a non-targeting 21 nt siRNA recommended as a negative control for experiments using targeted siRNA transfection.
Other Notes
Small volumes of JAK2 sirna vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Related Product Information for
JAK2 sirna
siRNA to inhibit JAK2 expression using RNA interference
Applications Tested/Suitable for JAK2 sirna
RNA Interference (RNAi)
NCBI/Uniprot data below describe general gene information for JAK2. It may not necessarily be applicable to this product.
NCBI Accession #
NP_004963.1
[Other Products]
NCBI GenBank Nucleotide #
NM_004972.3
[Other Products]
UniProt Primary Accession #
O60674
[Other Products]
UniProt Secondary Accession #
O14636; O75297[Other Products]
UniProt Related Accession #
O60674[Other Products]
Molecular Weight
130,674 Da
NCBI Official Full Name
tyrosine-protein kinase JAK2
NCBI Official Synonym Full Names
Janus kinase 2
NCBI Official Symbol
JAK2 [Similar Products]
NCBI Official Synonym Symbols
JTK10; THCYT3
[Similar Products]
NCBI Protein Information
tyrosine-protein kinase JAK2
UniProt Protein Name
Tyrosine-protein kinase JAK2
UniProt Synonym Protein Names
Janus kinase 2; JAK-2
Protein Family
Tyrosine-protein kinase
UniProt Gene Name
JAK2 [Similar Products]
UniProt Synonym Gene Names
JAK-2 [Similar Products]
UniProt Entry Name
JAK2_HUMAN
NCBI Summary for JAK2
This gene product is a protein tyrosine kinase involved in a specific subset of cytokine receptor signaling pathways. It has been found to be constituitively associated with the prolactin receptor and is required for responses to gamma interferon. Mice that do not express an active protein for this gene exhibit embryonic lethality associated with the absence of definitive erythropoiesis. [provided by RefSeq, Jul 2008]
UniProt Comments for JAK2
JAK2: a non-receptor tyrosine-kinase involved in a specific subset of cytokine receptor signaling pathways, including IL-3, -5 and GM-CSF. Interacts with IL23R, SKB1 and STAM2. It has been found to be constitutively associated with the prolactin receptor and is required for responses to gamma interferon. Mice that do not express an active protein for this gene exhibit embryonic lethality associated with the absence of definitive erythropoiesis. Fusion of Jak2 to TEL1 (ETV6) by t(9;12)(p24;p13) causes myeloproliferative disease in humans and mouse models. The Jak inhibitor AG490 inhibits constitutive Jak2 phosphorylation and causes apoptosis in cells from breast cancer and relapsing acute lymphoblastic leukemia. A single activating mutation is associated with several hematological malignancies. Inhibitor: AG490.
Protein type: Kinase, protein; Oncoprotein; Protein kinase, tyrosine (non-receptor); EC 2.7.10.2; Protein kinase, TK; TK group; JakA family
Chromosomal Location of Human Ortholog: 9p24
Cellular Component: nucleoplasm; extrinsic to internal side of plasma membrane; nuclear matrix; cytoskeleton; cytoplasm; caveola; cytosol; nucleus; lipid raft
Molecular Function: protein C-terminus binding; histone binding; non-membrane spanning protein tyrosine kinase activity; acetylcholine receptor binding; protein kinase binding; interleukin-12 receptor binding; protein kinase activity; protein binding; growth hormone receptor binding; peptide hormone receptor binding; insulin receptor substrate binding; protein-tyrosine kinase activity; heme binding; phosphoinositide 3-kinase binding; SH2 domain binding; type 1 angiotensin receptor binding; ATP binding; receptor binding
Biological Process: establishment and/or maintenance of chromatin architecture; positive regulation of nitric oxide biosynthetic process; activation of MAPKK activity; tyrosine phosphorylation of Stat3 protein; response to lipopolysaccharide; tyrosine phosphorylation of JAK2 protein; enzyme linked receptor protein signaling pathway; protein amino acid phosphorylation; positive regulation of tyrosine phosphorylation of Stat3 protein; regulation of apoptosis; response to antibiotic; elevation of cytosolic calcium ion concentration; tumor necrosis factor-mediated signaling pathway; erythrocyte differentiation; mesoderm development; negative regulation of neuron apoptosis; positive regulation of DNA binding; positive regulation of cell activation; positive regulation of protein import into nucleus, translocation; axon regeneration; positive regulation of insulin secretion; positive regulation of tumor necrosis factor production; JAK-STAT cascade; tyrosine phosphorylation of Stat5 protein; positive regulation of phosphoinositide 3-kinase cascade; tyrosine phosphorylation of STAT protein; positive regulation of peptidyl-tyrosine phosphorylation; response to hydroperoxide; mineralocorticoid receptor signaling pathway; tyrosine phosphorylation of Stat1 protein; positive regulation of transcription from RNA polymerase II promoter; positive regulation of transcription factor activity; positive regulation of cell differentiation; positive regulation of nitric-oxide synthase biosynthetic process; positive regulation of phosphoprotein phosphatase activity; peptidyl-tyrosine phosphorylation; negative regulation of heart contraction; hormone-mediated signaling; apoptosis; protein amino acid autophosphorylation; platelet-derived growth factor receptor signaling pathway; signal transduction; host programmed cell death induced by symbiont; negative regulation of cell proliferation; actin filament polymerization; positive regulation of cell proliferation; cell differentiation; STAT protein nuclear translocation; caspase activation; cell migration; cytokine and chemokine mediated signaling pathway; negative regulation of DNA binding; regulation of cell proliferation; positive regulation of interleukin-1 beta production; G-protein coupled receptor protein signaling pathway; positive regulation of tyrosine phosphorylation of Stat5 protein; regulation of inflammatory response; innate immune response; negative regulation of cell-cell adhesion; blood coagulation; cell motility; induction of apoptosis by oxidative stress; positive regulation of cell migration; positive regulation of inflammatory response
Disease: Polycythemia Vera; Myelofibrosis; Budd-chiari Syndrome; Erythrocytosis, Familial, 1; Thrombocythemia 3
Research Articles on JAK2
1. AURKA regulates JAK2-STAT3 activity in human gastric and esophageal cancers
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
